In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia - Rolipram and prednisolone active in cells from patients with poor prognosis

European Journal of Haematology

Volumn 83, Issue 1, 2009, Pages 22-34

  Lindhagen, Elin ^b   Norberg, Maria ^b   Kanduri, Meena ^b   Tobin, Gerard ^b   Säisänen, Laura ^b   Åberg, Magnus ^b   Gustafsson, Mats G ^b   Sundström, Christer ^b   Rosenquist, Richard ^b   Åleskog, Anna ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cellular drug sensitivity; Chronic lymphocytic leukemia; Genomic aberrations; IGHV mutation status; Prednisolone; Rolipram

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; BAG 1 PROTEIN; BORTEZOMIB; CELL NUCLEUS RECEPTOR; CHLORAMBUCIL; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEFITINIB; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN; HYDROXYCHLOROQUINE; I KAPPA B ALPHA; IDARUBICIN; IMATINIB; IMMUNOGLOBULIN HEAVY CHAIN; MIDOSTAURIN; MITOXANTRONE; PREDNISOLONE; ROLIPRAM; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SPECIFICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CASE CONTROL STUDY; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 17; CLASSIFICATION; DRUG SCREENING; GENETICS; IMMUNOGLOBULIN HEAVY CHAIN GENE; IN VITRO STUDY; MIDDLE AGED; MUTATION; TRISOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PREDNISOLONE; PROGNOSIS; RECEPTORS, GLUCOCORTICOID; ROLIPRAM; TRISOMY;

EID: 67649528133     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01248.x     Document Type: Article

References (45)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1910 6.
2. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999 94 : 1840 7.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999 94 : 1848 54.
4. Thorselius M, Krober A, Murray F et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006 107 : 2889 94.
5. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007 21 : 1885 91.
6. Byrd JC, Lin TS, Grever MR. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies. Semin Oncol 2006 33 : 210 9.
7. Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, Crespo M, Montserrat E. Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006 70 : 214 7.
8. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 1999 35 : 424 32.
9. Bosanquet AG, Bosanquet MI. Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia. Leukemia 2000 14 : 712 5.
10. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003 10 : 477 84.
11. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994 8 : 1640 5.
12. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992 50 : 177 85.
13. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994 54 : 163 70.
14. Li AH, Rosenquist R, Forestier E, Holmberg D, Lindh J, Lofvenberg E, Roos G. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia: a comparative polymerase chain reaction study using multiple sets of primers. Eur J Haematol 1999 63 : 211 8.
15. Li AH, Rosenquist R, Forestier E, Lindh J, Roos G. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implications for minimal residual disease detection. Leuk Res 2001 25 : 1033 45.
16. Tobin G, Thunberg U, Johnson A et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003 101 : 4952 7.
17. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc 2008 3 : 1364 9.
18. Galigniana MD, Radanyi C, Renoir JM, Housley PR, Pratt WB. Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J Biol Chem 2001 276 : 14884 9.
19. Tiwari S, Dong H, Kim EJ, Weintraub L, Epstein PM, Lerner A. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 2005 69 : 473 83.
20. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005 25 : 4493 502.
21. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006 2 : 458 66.
22. Kivekas I, Tobin G, Thunberg U, Vilpo L, Sundstrom C, Rosenquist R, Vilpo J. Ex vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. Leuk Res 2003 27 : 337 41.
23. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006 20 : 1441 5.
24. Anderson JA, Woodcock TM, Harty JI, Knott AW, Edwards MJ. The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. Eur J Cancer 1995 31A : 714 7.
25. Stewart DJ, Dahrouge S, Agboola O, Girard A. Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 1997 32 : 161 8.
26. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984 17 : 188 90.
27. Drees M, Zimmermann R, Eisenbrand G. 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 1993 53 : 3058 61.
28. Merz KH, Marko D, Regiert T, Reiss G, Frank W, Eisenbrand G. Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth. J Med Chem 1998 41 : 4733 43.
29. McEwan DG, Brunton VG, Baillie GS, Leslie NR, Houslay MD, Frame MC. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res 2007 67 : 5248 57.
30. Goldhoff P, Warrington NM, Limbrick DD Jr., Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res 2008 14 : 7717 25.
31. Nishiyama S, Okudaira M, Saito N. Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats. Arch Toxicol 2006 80 : 88 97. (Pubitemid 43130233)
32. Fleischhacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 1992 26 : 59 64.
33. Krause W, Kuhne G, Sauerbrey N. Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers. Eur J Clin Pharmacol 1990 38 : 71 5.
34. Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res 2007 13 : 4920 7.
35. Pui CH, Dahl GV, Rivera G, Murphy SB, Costlow ME. The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia. Leuk Res 1984 8 : 579 85.
36. Kato GJ, Quddus FF, Shuster JJ, Boyett J, Pullen JD, Borowitz MJ, Whitehead VM, Crist WM, Leventhal BG. High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 1993 82 : 2304 9.
37. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003 24 : 488 522. (Pubitemid 37059110)
38. Haarman EG, Kaspers GJ, Veerman AJ. Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation. Br J Haematol 2003 120 : 919 29.
39. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-Marco J, Jorda J, Durantez A. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004 18 : 1391 400.
40. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000 164 : 2200 6.
41. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 125 : 294 317. (Pubitemid 38621761)
42. Thornton PD, Matutes E, Bosanquet AG et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003 82 : 759 65.
43. Aleskog A, Larsson R, Hoglund M, Kristensen J, Nygren P, Lindhagen E. In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia. Anticancer Drugs 2005 16 : 277 83.
44. Mentz F, Mossalayi MD, Ouaaz F, Baudet S, Issaly F, Ktorza S, Semichon M, Binet JL, Merle-Beral H. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 1996 88 : 2172 82.
45. Wiernik PH, Paietta E, Goloubeva O, et al. Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia 2004 18 : 1605 10.